Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

Articles

Role of Transplant in AML

March 8th 2021

Use of Omidubicel Therapy in Hematologic Malignancies

March 1st 2021

BMT CTN 1102 Study in High-Risk MDS

March 1st 2021

Novel Targets and Biomarkers in AML

February 22nd 2021

IDH1/2-Mutated Treatment-Naïve AML

February 22nd 2021

BCL2 Inhibition in AML: VIALE-A Study

February 15th 2021

Type 1/2 FLT3 Inhibitors in AML

February 15th 2021

Role of Dual Targeted Therapy in AML

February 8th 2021

Sequencing of FLT3 Inhibitors in AML

February 8th 2021

Management of AML: FLT3 Inhibitors and BCL2 Inhibitors

February 1st 2021

Role of FLT3 Inhibitors in Chemo-Ineligible AML

February 1st 2021

MRD Monitoring in FLT3 ITD AML

January 25th 2021

Assessing MRD Status in AML

January 25th 2021

Prognostic Significance of IDH Mutations in AML

January 21st 2021

FLT3 Testing for Treatment of AML

January 21st 2021

Molecular Testing in Community Practices

January 15th 2021

Role of Molecular Testing in AML

January 15th 2021

Treating Chronic Graft-vs-Host Disease

June 19th 2020

Shifting Paradigm in Treating Acute Graft-vs-Host Disease

June 19th 2020

Graft-vs-Host Disease Prophylaxis Clinical Trials

June 19th 2020